| Literature DB >> 35566647 |
Joo-Hee Hwang1,2, Jeong-Hwan Hwang1,2, Seung Yeob Lee2,3, Jaehyeon Lee2,3.
Abstract
Hypervirulent Klebsiella pneumoniae (hvKp) is an important strain that can cause multiple organ infections. Although hvKp infection cases are increasing, there is limited information on the prostatic abscesses caused by K. pneumoniae. Furthermore, the clinical significance of hvKp associated with K1 or K2 capsular types or virulence genes in prostatic abscesses remains unclear. Therefore, we aimed to elucidate the clinical and microbiological characteristics of prostatic abscesses caused by K. pneumoniae in relation to various virulence genes. A retrospective study was performed at a 1200-bed tertiary hospital between January 2014 and December 2019. Patients diagnosed with prostatic abscesses with K. pneumoniae isolated from blood, urine, pus, or tissue cultures were enrolled in this study. Our results demonstrate that 30.3% (10/33) of the prostatic abscesses were caused by K. pneumoniae. All strains isolated from patients with prostatic abscesses due to K. pneumoniae were the K1 capsular type, and eight patients (80.0%) carried rmpA and iutA genes that identified hvKp. These findings suggest that hvKp is an important pathogen in prostatic abscesses. Therefore, when treating patients with K. pneumoniae prostatic abscesses, attention should be paid to the characteristics of hvKp, such as bacteremia, multiorgan abscess formation, and metastatic spread.Entities:
Keywords: Klebsiella pneumoniae; hypervirulence; prostatic abscess
Year: 2022 PMID: 35566647 PMCID: PMC9099488 DOI: 10.3390/jcm11092521
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Clinical characteristics of the patients with prostatic abscesses caused by Klebsiella pneumoniae.
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | Case 8 | Case 9 | Case 10 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Age | 60 | 79 | 54 | 41 | 62 | 75 | 82 | 58 | 71 | 45 |
| Underlying disease | No | DM | DM | DM | Rectal cancer | Prostate cancer | Colon cancer | DM, alcoholic LC | DM, bladder cancer, s/p cystostomy | Heavy alcoholic |
| Type of infection | Community- acquired | Community-acquired | Community- acquired | Community- acquired | Community- acquired | Community- acquired | Hospital- acquired | Community- acquired | Community- acquired | Community- acquired |
| Tissue or Pus culture | KP | None | None | KP | KP | None | None | None | None | KP |
| Urine culture | None | KP | None | None | None | None | None | KP | KP | KP |
| Bacteremia | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes |
| Other involved sites | Liver | No | Lung, brain, eye | No | Rt. thigh, gluteal area, and abdominal cavity | No | No | Kidney | Kidney | Kidney |
| Chief complaint | RUQ pain, Fever | Dysuria, fever | Visual disturbance, fever | Dysuria, fever | Abdominal pain, fever | Dysuria, fever | Fever | Fever | Fever | Fever |
| Antibiotics | Ceftriaxone IV, levofloxacin PO | Ceftriaxone IV, cefixime PO | Ceftriaxone IV, moxifloxacin PO | Ceftriaxone IV, levofloxacin IV, PO | Piperacillin– | Ceftriaxone IV, levofloxacin PO | Meropenem IV | Meropenem IV, TMP-SMX PO, levofloxacin PO | Meropenem IV, levofloxacin PO | Meropenem IV, ciprofloxacin IV, PO |
| Procedure or Operation | PCD (liver) | TURP | Vitrectomy | TURP | Graft removal | No | No | No | No | TURP |
| Outcome | Recover | Recover | Recover | Recover | Death | Recover | F/U loss | Recover | Recover | Recover |
| Sequalae | No | No | Blindness | Neurogenic bladder | No | No | No | No | No | No |
| Recurrence | No | No | No | No | N/A | No | N/A | No | No | No |
| Urinalysis (normal range) | ||||||||||
| Protein (neg) | 1+ | 1+ | 1+ | 2+ | 1+ | 2+ | 1+ | 2+ | 1+ | Neg |
| RBC (1–4/HPF) | 5–9 | >30 | 1–4 | 26–30 | 0–2 | >30 | 3–5 | >30 | >30 | 0–2 |
| WBC (1–4/HPF) | >30 | >30 | >30 | >30 | 3–5 | >30 | 3–5 | >30 | >30 | >30 |
| Laboratory (scales) | ||||||||||
| WBC (×103/mm3) | 19.90 | 10.49 | 17.20 | 13.46 | 15.66 | 12.55 | 19.49 | 2.60 | 17.18 | 27.38 |
| Hb (g/dL) | 13.00 | 7.60 | 12.10 | 12.30 | 8.40 | 10.70 | 15.40 | 9.50 | 10.10 | 9.80 |
| Platelets (×103/mm3) | 358.00 | 116.00 | 242.00 | 279.00 | 438.00 | 170.00 | 102.00 | 44.00 | 434.00 | 116.00 |
| ESR (mm/hr) | 57.00 | 39.00 | 58.00 | 90.00 | 106.00 | 48.00 | 33.00 | 5.00 | 98.00 | 82.00 |
| CRP (mg/L) | 191.05 | 107.24 | 93.44 | 142.21 | 45.92 | 182.78 | 125.59 | 146.84 | 138.69 | 172.53 |
| AST (IU/L) | 59.00 | 33.00 | 39.00 | 16.00 | 17.00 | 38.00 | 167.00 | 117.00 | 15.00 | 162.00 |
| ALT (IU/L) | 109.00 | 16.00 | 52.00 | 18.00 | 23.00 | 17.00 | 164.00 | 30.00 | 16.00 | 119.00 |
| BUN (mg/dL) | 18.00 | 17.00 | 19.00 | 20.00 | 8.00 | 26.00 | 21.00 | 57.00 | 25.00 | 20.00 |
| Creatinine (mg/dL) | 0.70 | 0.79 | 0.79 | 0.61 | 0.52 | 2.02 | 1.03 | 2.11 | 1.40 | 1.36 |
| PSA (0–4 ng/mL) | 27.44 | 35.12 | 0.28 | 5.36 | N/A | 6.00 | 125.41 | N/A | N/A | 0.97 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C-reactive protein; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; F/U, follow-up; Hb, hemoglobin; HPF, high-power field; IV, intravenous; KP, K. pneumoniae; LC, liver cirrhosis; N/A, not available; PCD, percutaneous catheter drainage; PO, per os; PSA, prostate-specific antigen; RBC, red blood cells; RUQ, right upper quadrant; TMP-SMX, trimethoprim–sulfamethoxazole; s/p, status post; TURP, transurethral radical prostatectomy; WBC, white blood cells.
Virulence factors and serotypes of Klebsiella pneumoniae isolates in patients with prostatic abscesses.
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | Case 8 | Case 9 | Case 10 | |
|---|---|---|---|---|---|---|---|---|---|---|
|
| + | + | + | + | - | + | - | + | + | + |
|
| + | + | + | + | - | + | - | + | + | + |
|
| + | + | + | + | - | + | - | + | + | + |
|
| + | + | + | + | + | + | + | + | + | + |
|
| + | + | + | + | - | + | - | + | + | + |
|
| + | + | + | + | + | + | + | + | + | + |
|
| + | - | + | + | - | + | - | + | + | + |
| Serotype | K1 | K1 | K1 | K1 | K1 | K1 | K1 | K1 | K1 | K1 |
| ESBL | - | - | - | - | - | - | + | - | + | - |
+, positive; -, negative; ESBL, extended-spectrum beta-lactamases.
Antibiotic resistance in patients with prostatic abscesses caused by Klebsiella pneumoniae.
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | Case 8 | Case 9 | Case 10 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Amikacin | S | S | S | S | S | S | S | S | S | S |
| Amp-sulb | S | S | S | S | S | S | R | S | R | S |
| Aztreonam | S | S | S | S | S | S | R | S | R | S |
| Ceftazidime | S | S | S | S | S | S | R | S | R | S |
| Cefazolin | S | S | S | S | S | S | R | S | R | S |
| Gentamicin | S | S | S | S | S | S | R | S | S | S |
| TMP-SMX | S | S | S | S | S | S | R | S | S | S |
| Pip-tazo | S | S | S | S | S | S | I | S | S | S |
| Ertapenem | S | S | S | S | S | S | S | S | S | S |
| Meropenem | S | S | S | S | S | S | S | S | S | S |
| Cefepime | S | S | S | S | S | S | R | S | R | S |
| Cefotaxime | S | S | S | S | S | S | R | S | R | S |
| Cefoxitin | S | S | S | S | S | S | S | S | S | S |
| Levofloxacin | S | S | S | S | S | S | R | S | S | S |
| Tigecycline | S | S | S | S | S | S | R | S | S | S |
Amp-sulb, ampicillin–sulbactam; I, indeterminate; Pip-tazo, piperacillin–tazobactam; R, resistant; S, susceptible; TMP-SMX, trimethoprim–sulfamethoxazole.